Address: PO Box 781247
Sandton 2146
Gauteng,South Africa
Tel: +27 11 883 5630
Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout our long history, we have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. We are committed to developing products not only to treat life-threatening conditions, but importantly, to improve the quality of life for patients with a variety of acute and chronic illnesses. We have a long-standing tradition of building high quality relationships based on the highest standards, with patients, physicians, employees, partners and other key stakeholders.
In the last fifteen years, we have focused on expanding our pan-European infrastructure, and have moved to strengthen the Research & Development base of the company.
In addition to developing, manufacturing and marketing our own pharmaceutical products, Norgine is an ideal partner for companies seeking assistance in the development and commercialisation of innovative pharmaceutical products across Europe. We value our development partnerships as, together with our own in-house product development, they support our growth ambitions and will help to facilitate our continued business expansion.
We have the resources to bring products to market on a pan-European or single country basis by combining sales and marketing expertise with all development, clinical research, product registration or manufacturing resources that our partners require.
In the years ahead, Norgine will continue to implement this successful strategy, building on our established infrastructure, strengthening our pan-European presence and collaborating with like-minded companies and organisations. By consolidating our successes, we can ensure we meet the challenges of an exciting future.
South Africa carries one of the world’s most disproportionate disease burdens, the worst of so-called westernised diseases, such as cardiac disease, diabetes etc on the one hand and the developmental…
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Focus Reports is back in South Africa as part of a second set of reports on the BRICS. What would you say are the main changes in the market since…
South Africa is at the moment one of the world’s most exciting and dynamic markets at the moment as Mr. Omar Ehsan was telling us, the most exciting market he…
Could you introduce to our readers MC Pharma’s business model in the South African market as well as the main milestones in the company’s development over the recent years? MC…
Mr. Daniel, after working with Pfizer Australia, working in Hong Kong as Regional Marketing Director for the Asian operation and in Japan, you have been the first South African appointed…
South Africa has recently achieved the 1st Millennium Development Goal (MDG) – reducing the proportion of the population living on less than 1 USD a day by half – but…
Our international readers know about South Africa’s socio-economic relative achievements, considering the country joined the BRICS grouping last year and achieved the first Millennium Development Goal (MDG) that same year.…
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
The story of Novo Nordisk South Africa began in 1959 in Johannesburg. It was among the first affiliates outside of Denmark, with insulin and anti-infectives produced locally. To what extent…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
See our Cookie Privacy Policy Here
